Retatrutide
As of the edition of 20 October 2026, Retatrutide is a protein: in active development; acts on GCGR, GIPR and GLP1R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2029
- Kind
- Protein
- Registered trials
- 34, 0 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Nervous system; Pregnancy and women's health; Urinary and reproductive; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Retatrutide.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 15 | 14 | 1 | 0 |
| Phase 2 | 4 | 3 | 1 | 0 |
| Phase 3 | 14 | 5 | 9 | 0 |
| All trials | 34 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Hudson Biotech | Lead sponsor of trials | 2026 to now |
| Eli Lilly | Lead sponsor of trials |